Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 10/2015

01.10.2015 | Fertility Preservation

Outcomes of ovarian stimulation after treatment with chemotherapy

verfasst von: Jessica L. Chan, Lauren N. C. Johnson, Brenda L. Efymow, Mary D. Sammel, Clarisa R. Gracia

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemotherapeutic agents have a known gonadotoxic effect; however, it is difficult to predict the impact they may have on ovarian stimulation. The objective of this study was to evaluate response to ovarian stimulation in patients exposed to chemotherapy compared with patients who were chemotherapy-naïve.

Methods

A retrospective cohort study of 130 patients with cancer or autoimmune disease was performed. Demographics, ovarian reserve, ovarian response and stimulation parameters, and oocyte data were compared between patients who were pre- and post-chemotherapy. Logistic regression modeling was performed to identify risk factors for cancellation and low oocyte yield, adjusting for confounders as appropriate.

Results

Antral follicle count (AFC) was significantly lower in post-chemo patients (9 vs. 17, p < 0.001). Post-chemotherapy patients were more likely to be cancelled during stimulation (23 vs. 4 %, p = 0.003). Among those that went to retrieval, there was no difference in total number of oocytes (10 vs. 10, p = 0.31) or mature oocytes retrieved (8 vs. 8, p = 0.38), despite higher starting (300 vs. 450 IU, p < 0.001) and total gonadotropin (3075 vs. 4612.5 IU, p = 0.008) doses in post-chemotherapy patients. Low AFC (≤6) was associated with cycle cancellation (OR 7.7, 95 % CI 1.8–33.2) and low oocyte yield (<6) (OR 5.4, 95 % CI 1.6–17.7).

Conclusions

Patients post-chemotherapy have lower AFC compared with the chemotherapy-naïve and have higher cancellation rates. Among those who underwent oocyte retrieval, oocyte yield was similar in both groups. Low AFC was most strongly associated with cycle cancellation and oocyte yield. Post-chemotherapy patients had higher rates of cycle cancellation but did equally well as pre-chemotherapy patients if they reached retrieval.
Literatur
1.
Zurück zum Zitat Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(16):2677–85. doi:10.1200/JCO.2008.20.1541.CrossRef Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(16):2677–85. doi:10.​1200/​JCO.​2008.​20.​1541.CrossRef
2.
Zurück zum Zitat Miller 3rd JJ, Williams GF, Leissring JC. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med. 1971;50(4):530–5.CrossRefPubMed Miller 3rd JJ, Williams GF, Leissring JC. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med. 1971;50(4):530–5.CrossRefPubMed
3.
Zurück zum Zitat Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer. 1985;55(10):2364–72.CrossRefPubMed Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer. 1985;55(10):2364–72.CrossRefPubMed
4.
Zurück zum Zitat Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Human Reprod (Oxford, England). 1993;8(12):2080–7. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Human Reprod (Oxford, England). 1993;8(12):2080–7.
6.
Zurück zum Zitat Hensley ML, Reichman BS. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Crit Rev Oncol/Hematol. 1998;28(2):121–8.CrossRef Hensley ML, Reichman BS. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Crit Rev Oncol/Hematol. 1998;28(2):121–8.CrossRef
7.
Zurück zum Zitat Wallace WH, Blacklay A, Eiser C, Davies H, Hawkins M, Levitt GA, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ. 2001;323(7307):271–4.PubMedCentralCrossRefPubMed Wallace WH, Blacklay A, Eiser C, Davies H, Hawkins M, Levitt GA, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ. 2001;323(7307):271–4.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril. 1986;45(4):443–59.PubMed Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril. 1986;45(4):443–59.PubMed
10.
Zurück zum Zitat Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res. 2011;63(12):1777–81. doi:10.1002/acr.20605.CrossRef Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res. 2011;63(12):1777–81. doi:10.​1002/​acr.​20605.CrossRef
11.
Zurück zum Zitat Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25(1):11–5. doi:10.1002/hon.802.CrossRefPubMed Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25(1):11–5. doi:10.​1002/​hon.​802.CrossRefPubMed
14.
15.
Zurück zum Zitat Barton SE, Najita JS, Ginsburg ES, Leisenring WM, Stovall M, Weathers RE, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013;14(9):873–81. doi:10.1016/S1470-2045(13)70251-1.CrossRefPubMed Barton SE, Najita JS, Ginsburg ES, Leisenring WM, Stovall M, Weathers RE, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013;14(9):873–81. doi:10.​1016/​S1470-2045(13)70251-1.CrossRefPubMed
23.
Zurück zum Zitat Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003;88(11):5307–14. doi:10.1210/jc.2003-030352.CrossRefPubMed Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003;88(11):5307–14. doi:10.​1210/​jc.​2003-030352.CrossRefPubMed
26.
Zurück zum Zitat Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril. 2001;75(4):705–10.CrossRefPubMed Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril. 2001;75(4):705–10.CrossRefPubMed
27.
Zurück zum Zitat Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril. 1998;69(3):505–10.CrossRefPubMed Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril. 1998;69(3):505–10.CrossRefPubMed
28.
Zurück zum Zitat Frattarelli JL, Levi AJ, Miller BT, Segars JH. A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. Fertil Steril. 2003;80(2):350–5.CrossRefPubMed Frattarelli JL, Levi AJ, Miller BT, Segars JH. A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. Fertil Steril. 2003;80(2):350–5.CrossRefPubMed
30.
Zurück zum Zitat Melo MA, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A, et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril. 2009;91(1):148–56. doi:10.1016/j.fertnstert.2007.11.042.CrossRefPubMed Melo MA, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A, et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril. 2009;91(1):148–56. doi:10.​1016/​j.​fertnstert.​2007.​11.​042.CrossRefPubMed
31.
33.
Zurück zum Zitat Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013;99(6):1644–53. doi:10.1016/j.fertnstert.2012.12.048.CrossRefPubMed Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013;99(6):1644–53. doi:10.​1016/​j.​fertnstert.​2012.​12.​048.CrossRefPubMed
34.
Zurück zum Zitat Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online. 2007;14(5):602–10.CrossRefPubMed Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online. 2007;14(5):602–10.CrossRefPubMed
35.
Zurück zum Zitat La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30. doi:10.1093/humupd/dmp036.CrossRefPubMed La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30. doi:10.​1093/​humupd/​dmp036.CrossRefPubMed
36.
Zurück zum Zitat Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010;93(3):855–64. doi:10.1016/j.fertnstert.2008.10.042.CrossRefPubMed Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010;93(3):855–64. doi:10.​1016/​j.​fertnstert.​2008.​10.​042.CrossRefPubMed
37.
Zurück zum Zitat Lee RK, Wu FS, Lin MH, Lin SY, Hwu YM. The predictability of serum anti-Mullerian level in IVF/ICSI outcomes for patients of advanced reproductive age. Reprod Biol Endocrinol : RB&E. 2011;9:115. doi:10.1186/1477-7827-9-115.CrossRef Lee RK, Wu FS, Lin MH, Lin SY, Hwu YM. The predictability of serum anti-Mullerian level in IVF/ICSI outcomes for patients of advanced reproductive age. Reprod Biol Endocrinol : RB&E. 2011;9:115. doi:10.​1186/​1477-7827-9-115.CrossRef
39.
41.
Zurück zum Zitat Green DM, Sklar CA, Boice Jr JD, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(14):2374–81. doi:10.1200/jco.2008.21.1839.CrossRef Green DM, Sklar CA, Boice Jr JD, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(14):2374–81. doi:10.​1200/​jco.​2008.​21.​1839.CrossRef
Metadaten
Titel
Outcomes of ovarian stimulation after treatment with chemotherapy
verfasst von
Jessica L. Chan
Lauren N. C. Johnson
Brenda L. Efymow
Mary D. Sammel
Clarisa R. Gracia
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 10/2015
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-015-0575-2

Weitere Artikel der Ausgabe 10/2015

Journal of Assisted Reproduction and Genetics 10/2015 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.